홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Valdecoxib

HCID 119607
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
181695-72-7
표준 SMILES
Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1
InChIKey
LNPDTQAFDNKSHK-UHFFFAOYSA-N
분자식
C16H14N2O3S
평균 분자량
314.4 g/mol
단동위원소 질량
314.07251349

개요

Valdecoxib is a member of the class of isoxazoles that is isoxazole which is substituted at positions 3, 4 and 5 by phenyl, p-sulfamoylphenyl and methyl groups, respectively. A selective cyclooxygenase 2-inhibitor, it used as a nonsteroidal anti-inflammatory drug (NSAID) for the treatment of arthritis from 2001 until 2005, when it was withdrawn following concerns of an associated increased risk of heart attack and stroke. It has a role as a non-steroidal anti-inflammatory drug, a non-narcotic analgesic, an antipyretic, an antirheumatic drug and a cyclooxygenase 2 inhibitor. It is a sulfonamide and a member of isoxazoles.

이름 및 식별자

우선 이름
Valdecoxib
IUPAC
4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide
영어명
Valdecoxib
분자식
C16H14N2O3S
분자량
314.36

이름 및 동의어

Valdecoxib181695-72-7Bextra4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamideValdynSC-65872SC 658724-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamidevaldecoxibum4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamidep-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamideDTXSID6044226
이름 더 보기
ValzValusCS-592ValecoxibAKOS 92130VatdecoxibValdecoxib 98%
NSC-7598464-(5-methyl-3-phenyl-isoxazol-4-yl)benzenesulfonamide2919279Q3WDTXCID4024226CHEBI:636344-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamideRefChem:56405M01AH03

데이터베이스 식별자

CAS
181695-72-7
PubChem CID
119607
DTXSID
DTXSID6044226
ChEMBL
CHEMBL865
ChEBI
CHEBI:63634
UNII
2919279Q3W

물성

구조 계산 물성

XLogP
2.6
극성 표면적
94.6 Ų
수소 결합 공여자 수
1
수소 결합 수용자 수
5
회전 가능 결합 수
3
무거운 원자 수
22
형식 전하
0
복잡도
462

실험 및 물리화학적 성질

Drugs · 2건

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

LogP · 2건

log Kow = 2.67 /Estimated/

2.37

Color/FormWhite crystalline powder
Solubility · 3건

Soluble in methanol and ethanol; freely soluble in organic solvents and alkaline (pH=12) aqueous solution

Relatively insoluble in water (10 ug/mL) at 25 °C and pH 7

>47.2 [ug/mL] (The mean of the results at pH 7.4)

Human Drugs · 4건

Breast Feeding; Lactation; Milk, Human; Analgesic Agents; Anti-inflammatory Agents, Nonsteroidal

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Melting Point160 - 162 °C
Vapor Pressure4.6X10-10 mm Hg at 25 °C /Estimated/
Henry's Law ConstantHenry's Law constant = 2.2X10-11 atm-cu m/mol at 25 °C /Estimated/
Physical DescriptionSolid

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 6건

Warning

H361 (97.4%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]

P203, P260, P273, P280, P318, P319, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 39 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Warning

H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]

유해성 정보

Regulatory InformationREACH registered substance: 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide (EC: 448-010-8)
FDA Requirements · 1건

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl valdecoxib, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

Special ReportsChavez ML, DeKorte CJ; Valdecoxib: A Review; Clin Ther 25 (3): 817-51(2003)
Hazard Classes and Categories · 2건

Repr. 2 (100%)

Repr. 2 (97.4%)

안전 및 보호

Disposal Methods · 1건

SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational exposure or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal, aquatic, and plant life; and conformance with environmental and public health regulations.

화학 및 산업

약리 정보

ATC Code · 2건

M - Musculo-skeletal system

QM - Musculo-skeletal system

Protein Binding98%
Pharmacodynamics · 1건

Valdecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is classified as a nonsteroidal anti-inflammatory drug (NSAID). Valdecoxib is used for its anti-inflammatory, analgesic, and antipyretic activities in the management of osteoarthritis (OA) and for the treatment of dysmenorrhea or acute pain. Unlike celecoxib, valdecoxib lacks a sulfonamide chain and does not require CYP450 enzymes for metabolism.

Mechanism of Action · 2건

Both COX-1 and COX-2 catalyze the conversion of arachidonic acid to prostaglandin (PG) H2, the precursor of PGs and thromboxane. Valdecoxib selectively inhibits the cyclooxygenase-2 (COX-2) enzyme, important for the mediation of inflammation and pain. Unlike non-selective NSAIDs, valdecoxib does not inhibit platelet aggregation.

Valdecoxib is a nonsteroidal anti-inflammatory drug (NSAID) with antiinflammatory, analgesic, and antipyretic therapeutic effects. It has been proposed that valdecoxib inhibits the activity of the enzyme cyclooxygenase-2 (COX-2), resulting in a decreased formation of precursors of prostaglandins. However, unlike most NSAIDs, valdecoxib does not inhibit cyclooxygenase-1 (COX-1) isoenzyme in humans at therapeutic concentrations.

Biological Half-Life · 2건

8-11 hours

Elimination: 8 to 11 hours. Terminal: 8.11 hours.

Metabolism/Metabolites · 4건

Hepatic (involves CYP3A4 and 2C9)

One active metabolite of valdecoxib has been identified in human plasma at approximately 10% the concentration of valdecoxib. This metabolite, which is a less potent COX-2 specific inhibitor than the parent also undergoes extensive metabolism and constitutes <2% of the valdecoxib dose excreted in the urine and feces. Due to the low concentration in the systemic circulation, it is not likely to contribute significantly to the efficacy profile of valdecoxib.

In humans, valdecoxib undergoes extensive hepatic metabolism involving both P450 isoenzymes (3A4 and 2C9) and non-P450 dependent pathways (i.e., glucuronidation).

관련 반응

6건
반응 기록 만들기
HRID 393858 반응식
HRID 393858반응물로
HRID 890883 반응식
HRID 890883반응물로
HRID 936954 반응식
HRID 936954반응물로
HRID 1166283 반응식
HRID 1166283반응물로
HRID 1839558 반응식
HRID 1839558반응물로
HRID 2152321 반응식
HRID 2152321반응물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
EC Number
448-010-8、803-082-3
Nikkaji
J1.302.764A
Other Experimental PropertiesHydroxyl radical reaction rate constant = 1.3X10-11 cu cm/molec-sec at 25 °C /Estimated/

물리화학적 성질

녹는점
162 · 162-164°C
끓는 점
481.2 · 481.2±55.0 °C(Predicted)
밀도
1.303 · 1.303±0.06 g/cm3(Predicted)
저장 조건
room temp
용해도
25 mg/mL · DMSO: >25mg/mL
산도 계수 (pKa)
9.83 · 9.83±0.10(Predicted)
물리적 상태
가루
색상
흰색에서 황백색까지
Henry's Law Constant
4.5 · 4.5×105 mol/(m3Pa) at 25℃, HSDB (2015)
InChI
InChI=1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20)
InChIKey
LNPDTQAFDNKSHK-UHFFFAOYSA-N
SMILES
C1(S(N)(=O)=O)=CC=C(C2=C(C)ON=C2C2=CC=CC=C2)C=C1

화학적 성질

Valdecoxib is a white crystalline powder that is relatively insoluble in water (10 μg/mL) at 25°C and pH 7.0, soluble in methanol and ethanol, and freely soluble in organic solvents and alkaline (pH=12) aqueous solutions.

독성 정보

Interactions · 5건

Valdecoxib produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone; therefore, monitoring of lithium concentrations for signs of lithium toxicity is recommended during concurrent use; however, lithium has no effect on valdecoxib pharmacokinetics.

In clinical trials, concurrent use administration of valdecoxib 20 mg with multiple dose of ketoconazole and fluconazole produced increased plasma exposure of valdecoxib by 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole, the increase in plasma concentration of valdecoxib was due to the inhibition of valdecoxib metabolism via p450 2C9 and 3A4 by fluconazole and ketoconazole.

Single and multiple dose crossover studies of valdecoxib 40 mg twice daily for seven days with warfarin 1 to 8 mg daily were associated with significant increases in plasma exposures of warfarin and an increase in prothrombin time (measured as INR); while mean INR values were only slightly increased, the day-to-day variability in individual INR values increased; monitoring of INR is recommended for the first few weeks after valdecoxib is initiated or the dose is changed.

Concurrent use /of angiotensin-converting enzyme (ACE) inhibitors/ with valdecoxib may decrease the antihypertensive effects of ACE inhibitors; also, risk of renal failure is increased in patients taking these medications.

For more Interactions (Complete) data for VALDECOXIB (14 total), please visit the HSDB record page.

Environmental Fate · 3건

TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 190,000(SRC), determined from a structure estimation method(2), indicates that valdecoxib is expected to be immobile in soil(SRC). Volatilization of valdecoxib from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 2.2X10-11 atm-cu m/mole(SRC), determined using a fragment constant estimation method(3). Valdecoxib is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 4.6X10-10 mm Hg(SRC), determined from a fragment constant method(4). Biodegradation data were not available(SRC, 2005).

AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 190,000(SRC), determined from a structure estimation method(2), indicates that valdecoxib is expected to adsorb to suspended solids and sediment(SRC). Volatilization from water surfaces is not expected(3) based upon an estimated Henry's Law constant of 2.2X10-11 atm-cu m/mole(SRC), developed using a fragment constant estimation method(4). According to a classification scheme(5), an estimated BCF of 23(SRC), from an estimated log Kow of 2.67(6) and a regression-derived equation(7), suggests the potential for bioconcentration in aquatic organisms is low. Biodegradation data were not available(SRC, 2005).

ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), valdecoxib, which has an estimated vapor pressure of 4.6X10-10 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase valdecoxib may be removed from the air by wet and dry deposition(SRC).

Soil Adsorption/Mobility · 1건

Using a structure estimation method based on molecular connectivity indices(1), the Koc for valdecoxib can be estimated to be 190,000(SRC). According to a classification scheme(2), this estimated Koc value suggests that valdecoxib is expected to be immobile in soil.

Human Toxicity Excerpts · 4건

/SIGNS AND SYMPTOMS/ Symptoms of overdose may include lethargy, drowsiness, nausea, vomiting, and epigastric pain. These are usually reversible with supportive treatment. GI bleeding, hypertension, acute renal failure, respiratory depression, and coma may occur.Anaphylactoid reactions have been reported with therapeutic ingestion of NSAIDs, and may occur following an overdose.

/SIGNS AND SYMPTOMS/ Serious, potentially life-threatening skin reactions, including exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, or toxic epidermal necrolysis (TEN), have been reported during postmarketing surveillance of valdecoxib. Fatalities due to Stevens-Johnson syndrome or toxic epidermal necrolysis have been reported. While serious reactions may occur at any time during therapy with valdecoxib, the risk of such reactions appears to be highest within the first 2 weeks of therapy. While patients with a history of sulfonamide hypersensitivity may be at greater risk for skin reactions, patients without such a history also are at risk for serious skin reactions. These reactions are rare but have been reported at a greater frequency with valdecoxib than with other selective COX-2 inhibitors (e.g., celecoxib). Discontinue valdecoxib at the first appearance of a rash or any other manifestation of hypersensitivity.

/HUMAN EXPOSURE STUDIES/ Risk of potentially fatal GI ulceration, bleeding, and perforation. Most studies indicate less risk of GI ulceration than prototypical /SRP: NSAIDs/; however, the relative risk remains to be established. Use with caution in patients at risk for GI bleeding (e.g., history of GI bleeding or ulceration, treatment with oral corticosteroids or anticoagulants, longer duration of /SRP: NSAID/ therapy, geriatric patients, debilitation, smokers, or alcohol dependence). Consider alternative therapy in those at high risk for GI bleeding. ...

/HUMAN EXPOSURE STUDIES/ Severe (rarely fatal) anaphylactoid reactions have occurred in patients receiving /SRP: NSAIDs/, and anaphylactoid reactions (e.g., anaphylaxis, angioedema) have been reported during postmarketing surveillance of valdecoxib. Such reactions occurred in patients with or without a history of allergic-type reactions to sulfonamides. ...Cross-sensitivity between aspirin and other /SRP: NSAIDs/ may occur. Do not use in patients with bronchospastic aspirin sensitivity. Avoid use in patients with aspirin triad. Caution in patients with preexisting asthma, as bronchospasms may occur.

Artificial Pollution SourcesValdecoxib's production and use as an anti-inflammatory(1) may result in its release to the environment through various waste streams(SRC).
Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Valdecoxib

vLess-DILI-concern

3

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Environmental Bioconcentration · 1건

An estimated BCF of 23 was calculated for valdecoxib(SRC), using an estimated log Kow of 2.67(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is low.

Volatilization from Water/Soil · 1건

The Henry's Law constant for valdecoxib is estimated as 2.2X10-11 atm-cu m/mole(SRC) using a fragment constant estimation method(1). This Henry's Law constant indicates that valdecoxib is expected to be essentially nonvolatile from water surfaces(2). Valdecoxib's Henry's Law constant indicates that volatilization from moist soil surfaces is not expected to occur(SRC). Valdecoxib is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 4.6X10-10 mm Hg(SRC), determined from a fragment constant method(3).

Non-Human Toxicity Excerpts · 5건

/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Valdecoxib was not carcinogenic in rats given oral doses up to 7.5 mg/kg/day for males and 1.5 mg/kg/day for females or in mice given oral doses up to 25 mg/kg/day for males and 50 mg/kg/day for females for two years.

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Valdecoxib did not impair male rat fertility at oral doses up to 9.0 mg/kg/day.

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ In female rats, a decrease in ovulation with increased pre- and post-implantation loss resulted in decreased live embryos/fetuses at doses > or = 2 mg/kg/day. The effects on female fertility were reversible. This effects is expected with inhibition of prostaglandin synthesis and is not the result of irreversible alteration of female reproductive function.

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ The incidence of fetuses with skeletal anomalies such as semi-bipartite thoracic vertebra centra and fused sternebrae was slightly higher in rabbits at the oral dose of 40 mg/kg/day throughout organogenesis. Valdecoxib was not teratogenic in rabbits up to an oral dose of 10 mg/kg/day.

/GENOTOXICITY/ In animal studies valdecoxib was not mutagenic in the Ames test or a mutation assay in Chinese hamster ovary (CHO) cells. No clastogenic effect was observed in the chromosome aberration assay in CHO cells or in in vivo micronucleus test in rat bone marrow.

Environmental Abiotic DegradationValdecoxib is not expected to undergo hydrolysis in the environment due to the lack of hydrolyzable functional groups(1).
Probable Routes of Human Exposure · 1건

Occupational exposure to valdecoxib may occur through inhalation and dermal contact with this compound at workplaces where valdecoxib is produced or used. The general population is exposed via ingestion of valdecoxib by its use as a drug. (SRC)

Environmental Fate/Exposure Summary · 1건

Valdecoxib's production and use as an anti-inflammatory may result in its release to the environment through various waste streams. If released to air, an estimated vapor pressure of 4.6X10-10 mm Hg at 25 °C indicates valdecoxib will exist solely in the particulate phase in the ambient atmosphere. Particulate-phase valdecoxib will be removed from the atmosphere by wet and dry deposition. If released to soil, valdecoxib is expected to have no mobility based upon an estimated Koc of 190,000. Volatilization from moist soil surfaces is not expected to be an important fate process based upon an estimated Henry's Law constant of 2.2X10-11 atm-cu m/mole. Valdecoxib is not expected to volatilize from dry soil surfaces based upon its vapor pressure. If released into water, valdecoxib is expected to adsorb to suspended solids and sediment based upon the estimated Koc. Volatilization from water surfaces is not expected to be an important fate process based upon this compound's estimated Henry's Law constant. An estimated BCF of 23 suggests the potential for bioconcentration in aquatic organisms is low. Hydrolysis is not expected to be an important environmental fate process since this compound lacks functional groups that hydrolyze under environmental conditions. Occupational exposure to valdecoxib may occur through inhalation and dermal contact with this compound at workplaces where valdecoxib is produced or used. The general population is exposed via ingestion of valdecoxib by its use as a drug. (SRC)

규제 정보

FDA Requirements · 1건

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl valdecoxib, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

안전 데이터

wgk
3
ridadr
UN 3077 9 / PGIII
risk_code
63-48/22-51/53
hazard_code
Xn,N
safety_code
36/37-61
Hazard Classifications
Aquatic Chronic 1Repr. 2STOT RE 2
스토리지 클래스
11 - Combustible Solids
유해 물질 데이터
181695-72-7(Hazardous Substances Data)

Valdecoxib has known human metabolites that include 4-[5-(hydroxymethyl)-3-phenyl-1,2-oxazol-4-yl]benzene-1-sulfonamide and 4-[3-(3-hydroxyphenyl)-5-methyl-1,2-oxazol-4-yl]benzene-1-sulfonamide.

MeSH Pharmacological ClassificationA subclass of cyclooxygenase inhibitors with specificity for CYCLOOXYGENASE-2.
Absorption, Distribution and Excretion · 6건

Oral bioavailability is 83%.

Valdecoxib is eliminated predominantly via hepatic metabolism with less than 5% of the dose excreted unchanged in the urine and feces. About 70% of the dose is excreted in the urine as metabolites, and about 20% as valdecoxib N-glucuronide.

86 L

oral cl=6 L/h

At recommended doses, the mean oral bioavailability is 83%. The peak plasma concentration and area under the plasma concentration-time curve are roughly proportional across the clinical dose range. Valdecoxib may be coadministered with meals. Peak-plasma concentrations and extent of absorption were not affected after valdecoxib was taken with a high fat meal.

Time to peak concentration: Approximately 3 hours. Note: Time to peak concentration was delayed by 1 to 2 hours when administered with a high fat meal.

Cellular LocationsMembrane
Metabolite PathwaysValdecoxib Action Pathway

용도 및 제조

Uses · 2건

Medication

Use (kg) in USA (2002): 1990

Formulations/PreparationsOral: Tablets, film-coated 10 mg (Bextra), (Pfizer); 20 mg (Bextra), (Pfizer).
Use ClassificationPharmaceuticals
General Manufacturing Information · 1건

Information available in 2005 indicated that Valdecoxib was used in the manufacture of pharmaceutical preparations in the following countries: Austria, Belgium, Chile, Colombia, Germany, India, Singapore, Switzerland, United Kingdom, United States (1,2)

응용 분야 · 3건

개요Valdecoxib is a second-generation COX-2 inhibitor, developed as a follow-up to celecoxib for the oral once-daily treatment of osteoarthritis, adult rheumatoid arthritis and menstrual pain. Valdecoxib is approximately 28,000-fold more selective against human recombinant COX-2 than human recombinant COX-1. In an ex viva human whole blood assay, the I&O values against COX-2 and COX-1 were respectively 0.89 PM and 25.4 FM. In animal models, valdecoxib possesses excellent oral activity as an antiinflammatory. In rats, valdecoxib potently inhibited carrageenan footpad edema and adjuvant-induced arthritis.

용도Valdecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic and antipyretic properties in animal models. It is a potent and selective inhibitor of prostaglandin synthesis primarily through inhibition of COX-2. Valdecoxib is used to relieve some symptoms caused by arthritis (rheumatism), such as inflammation, swelling, stiffness, and joint pain.

일반 설명Valdecoxib (VCX) is a diaryl substituted isoxazole compound. It comprises of sulfonyl propanamide and is a metabolite of parecoxib.

제조 방법 · 1건

The step for the synthesis of valdecoxib: Deoxybenzoin is converted to the corresponding oxime by treatment with hydroxylamine under basic conditions with sodium acetate in aqueous ethanol or in toluene in presence of potassium hydroxide in absolute ethanol. The treatment of the oxime under nitrogen with two equivalents of butyllithium in tetrahydrofuran is followed by cyclization in ethyl acetate or acetic anhydride to the isoxazoline derivative. Finally, treatment of the isoxazoline with cold chlorosulfuric acid followed by reaction of the intermediate with aqueous ammonia afforded valdecoxib.

상·하류 제품 정보

상류 원료

디펜히드라민히드록실아민아세트산 나트륨5-Methyl-3,4-diphenylisoxazole5-메틸-3,4-디페닐-4,5-디히드로이속사졸-5-OL

하류 제품

ParecoxibN-((4-(5-메틸-3-페닐이속사졸-4-일)페닐)술포닐)아세트아미드발데콕시브불순물B1-하이드록시발데콕시브
추가 설명 · 1건

정의ChEBI: Valdecoxib is a member of the class of isoxazoles that is isoxazole which is substituted at positions 3, 4 and 5 by phenyl, p-sulfamoylphenyl and methyl groups, respectively. A selective cyclooxygenase 2-inhibitor, it used as a nonsteroidal anti-inflammatory drug (NSAID) for the treatment of arthritis from 2001 until 2005, when it was withdrawn following concerns of an associated increased risk of heart attack and stroke. It has a role as a non-steroidal anti-inflammatory drug, a cyclooxygenase 2 inhibitor, a non-narcotic analgesic, an antirheumatic drug and an antipyretic. It is a member of isoxazoles and a sulfonamide.